{'fraction_non_alphanumeric': 0.027649769585253458, 'fraction_numerical': 0.02304147465437788, 'mean_word_length': 5.585858585858586, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Serum antibodies to the major HSV‐2‐ specified DNA‐binding protein in patients with an acute HSV infection or cervical neoplasia

The major HSV‐2‐specified DNA‐binding protein (ICSP 11/12) was purified from HSV‐infected cells. ELISA and immunoblotting techniques were used to study its antigenicity in HSV‐infected patients and patients with cervical neoplasia and control women. Patients with an acute HSV‐2 infection had clearcut antibody responses to the purified ICSP 11/12 preparation. Determination of the ICSP 11/12 antibodies by ELISA revealed considerably higher serum antibody levels in patients with cervical carcinoma than in the controls.